Autologous stem cell transplantation using unprocessed, G-CSF-mobilized whole blood (WB) is a simple, cost-reducing procedure and supports high-dose chemotherapy regimens not exceeding 72 h. Thereafter, clonogenic capacity rapidly decreases if routine anticoagulants are used for storage. In order to increase clinical applicability, we investigated the requirements for optimal preservation of unprocessed WB for 7 days. During storage at 22؇C in CPDA-1, a decrease in pH was noted, which was at least partially responsible for the low recovery of clonogenic cells. Subsequently, WB cells were stored in various cell culture media (RPMI 1640, ␣-MEM, X-VIVO15, CellGro SCGM and Leibovitz's L15 medium) containing either serum, serum-free substitutes or no additives. Leibovitz's L15 showed significantly better CFU-GM recoveries than the other media. Using a calcium-free modification of L15 medium (added 3:10 to WB), 94 ؎ 24% of CD34 ؉ cells, 41 ؎ 14% of BFU-E, 56 ؎ 17% CFU-GM and 90 ؎ 14% of LTC-IC were preserved during storage for 7 days at 22؇C. Storage at 4؇C was also feasible, but showed less optimal recoveries of 52 ؎ 29% (CD34), 32 ؎ 10% (BFU-E), 13 ؎ 7% (CFU-GM) and 58 ؎ 9% (LTC-IC). The expression of CD38, Thy-1, c-kit, AC133, L-selectin and CXCR4 on CD34-positive cells remained unchanged. In conclusion, a modified Leibovitz's L15 medium better meets the metabolic requirements of a high-density cell culture and allows safe storage of G-CSF mobilized WB for at least 7 days. The results encourage further exploration of WB transplants stored for 7 days for clinical use. Bone Marrow Transplantation (2001) 28, 145-155.
The use of peripheral blood stem cells instead of bone marrow has resulted in more rapid hematological recovery after autologous transplantation, leading to a significant reduction of morbidity and costs. 1 Peripheral blood stem cells (PBSC) are usually collected via leukapheresis after mobilization with G-CSF or chemotherapy and subsequently processed and frozen in specially equipped laboratories. A further reduction in costs can be achieved if, instead of leukapheresis, one liter of G-CSF primed whole blood (WB) is collected and re-infused unprocessed after high-dose chemotherapy. 2 Other advantages include the simplicity of the procedure and the low volume of blood involved. The latter could theoretically decrease the number of residual tumor cells in the transplant in comparison with a leukapheresis harvest, for which approximately 10 liters of blood is processed.
The most valuable prognostic factor for hematological recovery is the CD34-positive cell dose infused. Generally accepted is a minimal CD34-positive cell dose of 2.0 ϫ 10 6 per kg for safe recovery. However, for rapid platelet recovery higher cell doses are recommended. 3 Various authors have demonstrated that it is also possible to effectively mobilize 2.0 ϫ 10 6 CD34-positive cells per kg into 500-1000 ml of whole blood. [4] [5] [6] [7] So far, WB has been successfully applied after high-dose chemotherapy for multiple myeloma, non-Hodgkin's lymphoma and lung cancer. [8] [9] [10] However, a major disadvantage of WB is that the storage time is very limited. After only 72 h, the clonogenic potential of the graft rapidly decreases. 11, 12 Since most high-dose regimens cover more than 3 days, the number of clinical applications so far is limited. In order to increase clinical applicability, the period of unfrozen storage has to be extended.
The non-frozen storage of bone marrow and peripheral blood progenitors has been extensively studied. Using optimized cell concentrations (1-2 ϫ 10 6 /ml) and culture conditions, colony-forming cells could be preserved for 1 or more weeks. 13, 14 However, these methods are not suitable for storing hematopoietic progenitors for subsequent reinfusion because of the involvement of xenogeneic sera and volume requirements. Therefore, most studies aiming at clinical use evaluated CFU preservation after storage of either bone marrow or leukapheresis material at 4°C in CPD or ACD-A. In general, CFU-GM recovery after 72 h Bone Marrow Transplantation varied between 50 and 90%, whereas after 5-7 days only 0-20% recovery was found. 12, [15] [16] [17] [18] Data concerning optimal storage temperature are conflicting and vary from 4-22°C. 15, 17 All of these studies have in common the use of anti-coagulants optimised for red cell storage. These solutions may be less suitable for liquid storage of stem cell transplants, which in general have very high leukocyte counts.
In this study, we systematically investigated the specific requirements for optimal preservation of clonogenic cells in unprocessed G-CSF-mobilized WB in order to prolong the storage period to 7 days.
Materials and methods

Whole blood samples
G-CSF-mobilized blood was obtained from patients with various malignancies who were referred for peripheral blood stem cell collection (Table 1) . Patients were treated with filgrastim (Neupogen; Amgen, Thousand Oaks, CA, USA) or lenograstim (Granocyte; Rhone-Poulenc Rorer, Paris, France) subcutaneously daily with or without prior WBC ϭ white blood cell count (ϫ10 6 /ml). CFU/dish ϭ number of CFU-GM counted per assay. AML ϭ acute myeloid leukemia; NHL ϭ non-Hodgkin's lymphoma; ALL ϭ acute lymphoblastic leukemia. Mobilization: A: filgrastim 10 g/kg/day; B: filgrastim 2 ϫ 12 g/kg/day; C: lenograstim 10 g/kg/day after Ara-C/amsacrine; D: filgrastim 10 g/kg/day after Ara-C/etoposide; E: filgrastim 10 g/kg/day after prednisolone/etoposide/mitoxantrone; F: filgrastim 10 g/kg/day after ifosphamide/ etoposide/methotrexate (IMVP); G: filgrastim 10 g/kg/day after 5-fluorouracil/epirubicin/cyclophosphamide (FEC). chemotherapy (Table 1) . Prior to or during leukapheresis, 90 ml of whole blood (WB) was withdrawn into a 2,3-ethyl, hexyl-phtalate plasticized transfer bag (Nederlands Productie Laboratorium voor Bloedtransfusieapparatuur en Infusievloeistoffen BV (NPBI), Emmer-Compascuum, The Netherlands) containing 10 ml of 3.8% trisodium citrate as the anticoagulant. Informed consent was obtained according to the Declaration of Helsinki.
Storage conditions
In order to exclude differences due to inter-patient variation, each whole blood collection was divided into 4-10 samples and used to test several conditions simultaneously. The samples were kept in Nunclon polystyrene tissue culture flasks (Nunc A/S, Roskilde, Denmark) which were coated with 1:10 poly(2-hydroxyethyl methacrylate) (Sigma P-3932, Sigma-Aldrich, St Louis, MO, USA). 19 Culture medium was subsequently added as described below. Twenty-five cm 2 flasks were used for experiments with a total blood ϩ medium volume of 10 ml. Eighty cm 2 flasks were used for experiments with a total blood ϩ medium volume of 25-30 ml. The flasks were either kept closed or, if a medium with a bicarbonate buffer was used, opened in 5% CO 2 . The storage temperature was either 22°C (room temperature in an air-conditioned room) or 4°C (refrigerator). Initially, the flasks were slowly agitated, but this led to significant clumping of the white cells at 4°C, so the agitation was omitted. 20 No significant differences in recovery of clonogenic cells were found between agitation and no agitation at 22°C (data not shown). Samples of 100 ml were stored at 22°C in Lifecell PL732 Culture Bags (Nexell Therapeutics Inc, Irvine, CA, USA).
pH and CFU-GM recovery
In order to assess the effect of pH during storage on the recovery of CFU-GM, mononuclear cells (MNC) isolated from WB were incubated at 22°C in Hepes-buffered, bicarbonate-free Dulbecco's modified Eagle's medium (DMEM) containing 15% autologous serum and 50 mm Hepes. Prior to adding cells, the pH of the medium ϩ serum was adjusted at room temperature to 6.8 or 7.4 by titration with 1 m HCl or 1 m NaOH. Cells were incubated for 96 h in order to prevent an unacceptable decrease in pH. CFU-GM recovery was calculated by dividing the total number of colonies present after 96 h by the number of colonies in the initial culture.
Screening of cell culture media
Five different cell culture media with specific characteristics were tested for stem cell preservation and compared with citrate-phosphate-dextrose-adenine (CPDA-1; NPBI) or citrate (Na 3 citrate 3.8%; Merck, Darmstadt, Germany). CPDA-1 and citrate were both added to whole blood in a 1:10 ratio. Cell culture media were added to the blood cells after removal of plasma and citrate by three washes in phosphate-buffered saline in order to avoid interference by plasma glucose. In these experiments, the blood cells obtained from 3 ml of whole blood were suspended in medium to a final volume of 10 ml.
The characteristics of the various cell culture media are presented in Table 2 . Cell culture media were either used pure, or with serum-free substitutes or fetal calf serum (FCS) and horse serum (HS) to substitute for the plasma.
Modifications of Leibovitz's L15 medium
Further experiments were performed with Leibovitz's L15 medium, because this medium showed the most satisfying results (see Results). First, it was investigated whether the plasma of whole blood could replace the serum-free substitutes of this medium. For this purpose, a modified calciumfree Leibovitz's L15 medium (Ca-free L15) was obtained (custom-made by Gibco BRL, Life Technologies Inc, Rockville, MD, USA). Seven ml of this medium was directly added to 3 ml of citrated whole blood, without prior washing. When Ca-free L15 was used at 4°C, the pH was adjusted to 6.2 before adding the medium to the whole blood in order to maintain a pH of 7.4 at 4°C.
Next, experiments were performed to determine the most optimal ratio of Ca-free L15 medium/whole blood with regard to recovery of clonogenic cells and practical handBone Marrow Transplantation ling. Initially, the total volume had consisted of 70% medium. In these experiments, the amount of medium used was 10%, 30%, 50%, 70% or 90% of the total volume of 10 ml, respectively.
Routine blood tests
White blood cell counts (WBC) were measured on a Sysmex K4500 automated hematology analyzer (Toa, Kobe, Japan). Blood gas and pH analysis was performed using a Corning model 248 blood gas analyzer (Corning Inc, New York, NY, USA). All parameters were measured at 37°C, and subsequently corrected for the temperature of the condition concerned. Corrections were made using the oxygen status algorithm (OSA) software version 2.0 (copyright 1991 by Radiometer Medical A/S, Copenhagen, Denmark).
Culture assays
Colony-forming assays were performed using either MethoCult GF4534 or MethoCult GF4434 (with erythropoietin) complete methylcellulose culture medium (Stem Cell Technologies, Vancouver, Canada). For this purpose, mononuclear cells were isolated from the whole blood sample by using a Ficoll separation and subsequently plated into MethoCult. The number of colony-forming cells was calculated by multiplying the number of colonies formed per cell plated with the number of mononuclear cells isolated after Ficoll separation per whole blood volume sampled. Colonies were expressed per unit volume of WB instead of per 100 000 viable cells in order to avoid bias that could be introduced by differential cell loss. The variation of this method is however quite large, and therefore unprocessed whole blood was also plated into methylcellulose medium, as described elsewhere. 21 Briefly, heparinized samples were diluted in Iscove's medium until (1) the red blood cell count was 0.2 ϫ 10 9 /ml or lower; and (2) the number of clonogenic cells per ml was low enough to prevent overplating. The diluted whole blood sample was directly plated into methylcellulose culture medium. CFU-GM and BFU-E colonies were scored after 16 days of incubation at 37°C. CFU-GM colonies were scored if colonies consisted of 20 cells or more. BFU-E were defined as erythroid colonies containing Ͼ200 cells and consisting of three or more clusters. 22 Long-term culture-initiating cells (LTC-IC) were assayed at limiting dilution on a pre-established human bone marrow stromal layer as described elsewhere. 23, 24 Bone marrow for the stromal layers was obtained after informed consent from patients undergoing cardiac surgery. After 3-4 weeks of culture, the stroma was irradiated with 10 Gy and replated in 96-wells flat bottom culture plates (Costar, Corning). CD34-positive cells were positively selected from the whole blood using the MiniMACS technique (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) and plated into four different concentrations in 24 replicate wells after correction for purity. Half of the medium was refreshed at weekly intervals. Both the bone marrow and LTC-IC cultures were performed with ␣-MEM, supplemented with 12.5% FCS, 12.5% HS, 0.4 mg/ml l-glutamine, folic acid 10 g/ml, I-inositol 40 g/ml, 1% penicillin/streptomycin and ␤-mercapto-ethanol 10 Ϫ4 m (all from Gibco BRL). Hydrocortisone 10 Ϫ6 m (Pharmacia and Upjohn, Peapack, NJ, USA) was added freshly to the medium each week. After 5 weeks of culture at 37°C, the contents of all wells were harvested and plated into methylcellulose culture medium (MethoCult GF4534). After 2 more weeks, positive and negative wells were scored. The LTC-IC frequency among the CD34-positive cells from the cultures performed at limiting dilution was calculated with Poisson statistics using the maximum likelihood method, 25, 26 and the chi-squared test was used to check for linearity. The LTC-IC frequency per CD34-positive cell was used to determine the number of LTC-IC per ml of WB.
FACS analysis
Enumeration of the number of CD34-positive cells in whole blood was performed using the lyse-no-wash ProCount technique according to the manufacturer's instructions (Becton Dickinson (BD), San Jose, CA, USA). Gates were manually adjusted if necessary.
The viability of the CD34-positive cells was measured by using the DNA/RNA dye Syto16 (Molecular Probes, Eugene, OR, USA) in combination with 7-amino-actinomycin D (7-AAD, Via Probe; Pharmingen, San Diego, CA, USA). Syto16 can be used in combination with the Pgp-blocker PSC833 (kindly provided by Novartis, Basle, Switzerland) to detect early apoptotic CD34-positive cells. 27 In brief, mononuclear cells were isolated from whole blood samples by Ficoll separation. These cells were first incubated with APC-labeled anti-CD34 (8G12, BD) antibody. After washing, the cells were subsequently incubated with 7-AAD (for exclusion of dead cells) and 5 nm Syto16 in the presence of 1 m PSC833 in DMEM without phenol red or sodium bicarbonate for 45 min at 37°C in the dark. After washing in PBS/BSA 0.1%, the cells were kept on ice until FACS analysis. Due to the spectral properties of Syto16 (fluorescence in FL1, with spectral overlap in FL2 and FL3, which is the main problem at concentrations exceeding 5 nm) special attention had to be paid to compensate FL3 fluorescence (7-AAD) for Syto16 fluorescence in FL2.
For phenotypic analysis of CD34-positive cells, whole blood was incubated with APC-labeled anti-CD34 and PerCP-labeled anti-CD45 (2D1, BD) at a maximum WBC of 10 ϫ 10 6 /ml. FITC-labeled and PE-labeled antibodies were used to determine co-expression of primitive markers and adhesion molecules on CD34 ϩ CD45 ϩ cells. The following antibodies were used: anti-CD90-FITC (5E10, Pharmingen), anti-CD117-PE (95C3, Immunotech, Marseille, France), anti-AC133-PE (Miltenyi Biotech), anti-CD38-PE (HB-7, BD), anti-CD62L-PE (Dreg56, Pharmingen), anti-CD49d-PE (L25, BD), anti-CD49e-FITC (SAM1, Immunotech) and anti-CXCR4-FITC (12G5, R&D Systems, Minneapolis, MN, USA). Anti-IgG1-FITC, PE, PerCP and APC and anti-IgG2a-FITC antibodies were used as isotype controls. Flow cytometry was performed using a FACSCalibur (BD), equipped with an argon laser (488 nm wavelength) and a red diode laser (635 nm wavelength). The Cellquest software package (BD) was used to analyze data generated by flow cytometry.
The percentage of positive cells was corrected for the negative control. Fluorescence intensity was expressed as the mean fluorescence intensity (MFI): (mean fluorescence Moab) Ϫ (mean fluorescence isotype)/(mean fluorescence isotype).
Data analysis
All data were analyzed by using the Microsoft Excel 97 software package (Microsoft Corporation, Redmond, WA, USA). Non-parametric tests and correlation analysis were performed with the statistical software package SPSS release 7.5 (SPSS Inc, Chicago, IL, USA). Data were expressed as mean Ϯ standard deviation (s.d.), and the Student's t-test was used to compare means. If data were asymmetrically distributed, data were expressed as median and range and analyzed using the Mann-Whitney U test.
Results
Samples
The white blood cell counts (WBC), and the numbers of CD34-positive cells and CFU-GM per ml of the whole blood (WB) samples are presented in Table 1 . The median WBC was 19.0 ϫ 10 6 /ml (range 1.0-81.9). The median CD34-positive cel count per ml was 54 000 (range 4000-949 100).
Storage of whole blood in CPDA-1 and citrate
The anticoagulant citrate-phosphate-dextrose (CPD) currently used in blood banking and its modification CPDA are balanced for optimal preservation of red cells for 3-4 weeks. These anticoagulants mainly consist of glucose, with or without adenine. WB aliquots stored in CPDA-1 at 4°C showed no CFU-GM after 7 days (Table 3) . Changing the storage temperature to 22°C did not improve recovery, while a remarkable drop in pH was noted. Using citrate without glucose or further additives, a mean CFU-GM recovery of 20% after 7 days at 22°C was found while at the same time the pH remained normal. However, if citrate was used at 4°C, again hardly any CFU-GM could be detected (Table 3) .
pH and CFU-GM recovery
To investigate whether a low pH could, at least partially, be responsible for the differences in CFU-GM recovery, experiments were performed in which, except for the pH, all conditions were equal. For this purpose, MNC isolated from WB were incubated for 96 h at 22°C in a Hepes-buffered medium with a pH of either 6.8 or 7.4. During the incubation period, the pH decreased only slightly to 6.63 Table 3 CFU-GM recovery and pH in mobilized whole blood after storage for 7 days at 4°C or at 22°C with either CPDA-1 or citrate alone as anticoagulant 
Exp
Screening of CFU-GM recovery using various cell culture media
The stable pH in the citrate WB samples at 22°C (Table  3) could be responsible for the better CFU-GM recovery. The addition of extra nutrients to the anticoagulant might also improve CFU recovery, provide that the pH is controlled either by a strong buffer or by the presence of an alternative carbohydrate source that reduces lactate production. To test this hypothesis, mobilized WB samples were stored for 7 days at 22°C in the presence of five different cell culture media ( Table 2) after removal of plasma, and compared with an unprocessed citrate sample. The results are presented in Table 4 . Under all conditions, a decrease in pH was noted which was linearly related to the WBC count (data not shown). However, the decrease was more pronounced for RPMI 1640, X-VIVO15 and CellGro SCGM than for Leibovitz's L15 and ␣-MEM (Table 4) . The CFU-GM recovery after 7 days was significantly worse after storage in ␣-MEM, X-VIVO15 or CellGro SCGM (median recoveries of 1, 0 and 15%, respectively) in comparison with WB containing citrate only (median recovery of 22%; P Ͻ 0.05). However, enriched Leibovitz's L15 (with serum-free substitutes) showed a significantly better CFU-GM recovery (median 42%; P Ͻ 0.05) in comparison with citrate, RPMI 1640, ␣-MEM, X-VIVO15, CellGro SCGM and L15 (Table 4) .
Modifications of Leibovitz's L15 medium
CFU-GM were best preserved in Leibovitz's L15 with serum-free substitutes. Further experiments were carried out to investigate whether Leibovitz's L15 also supported stem cell preservation in a true whole blood sample containing plasma instead of serum-replacing substitutes. For this purpose, a calcium-free Leibovitz's L15 (Ca-free L15) was obtained, which could be directly added in combination with citrate to freshly collected whole blood. Using this 
s t-test).
d One sample showed a reduced CFU-GM growth at day 0 resulting in very high recoveries at day 7. SF ϭ Serum-free substitutes, consisting of human serum albumin (HSA) 10 g/l (CLB, Amsterdam, The Netherlands), folic acid 10 g/ml (Gibco BRL 13370-010), I-inositol 40 g/ml (Gibco BRL 13390-026), Human holo-transferrin 30 g/ml (Sigma T-0665), L-␣-phosphatidylcholin (from soybean) 30 g/ml (Sigma P-7443), cholesterol 7.5 g/ml (Sigma C-3045), Velosulin 0.29 IE/ml (Novo Nordisk), Monothioglycerol 1.6 ϫ 10 Ϫ4 m (Sigma M-6145). e Patented formula of unknown composition. FCS ϭ fetal calf serum; HS ϭ horse serum. modified medium, a median CFU-GM recovery of 43% (range 25-62%) was found after 7 days (Table 4) .
CD34 recovery after storage of mobilized WB
In contrast to the significant loss of CFU-GM during storage for 7 days in the various media, the number of CD34-positive cells remained much more constant during the storage period, showing only a median loss between 0 and 24% (Table 5) . We have recently found that after cryopreservation, 66% (range 14-96%) of the CD34-positive cells in leukapheresis material detected with routine protocols 28 are, in fact, early apoptotic and non-clonogenic. 27 Figure 1 shows an example of early apoptosis analysis of CD34-positive cells after 7 days in WB. Panel a shows a representative example of cryopreserved CD34-positive cells after thawing, demonstrating that here a major proportion of the cell population consisted of (early) apoptotic and dead cells Table 5 Recovery of CD34-positive cells after storage of mobilized whole blood for 7 days at 22°C in various cell culture media Table 5 , and indicate that in the tested samples the viability of the CD34 population was very high (Ͼ90%) without signs of early apoptosis, in contrast with the CD34-positive population in leukapheresis material after cryopreservation.
Ratio of medium/whole blood
So far, the total volume of whole blood and medium has consisted of 70% medium (Tables 4 and 5 ). To optimize the use of modified Ca-free L15 for storage of WB, different ratios of medium and whole blood were compared with respect to CFU-GM recovery after 7 days. A 10% medium volume (1:10 ratio, normally used for citrate anticoagulation) showed less optimal results than those presented in Table 4 (median recovery 24%, range 22-33% (n ϭ 4)). Medium volumes of 30%, 50%, 70% and 90% resulted in median CFU-GM recoveries of 37% (range 34-41%), 37% (range 21-44%), 41% (range 29-55%) and 30% (range 25-33%), respectively (n ϭ 4). Since a 30% medium volume is more practical in handling larger blood volumes, all further experiments were performed using this ratio (Table 6, Figures 2 and 3) .
Clonogenic ability of progenitors in mobilized whole blood after 7 days
To characterize the kinetics of the loss of clonogenic cells in WB over 7 days, daily samples were taken to assess the CD34-positive cell count and CFU-GM and BFU-E content per ml. Ca-free L15 WB was tested both at 22°C and 4°C, and compared with CPDA-1 at 4°C and citrate at 22°C (n ϭ 4). The results are presented in Figure 2 . Figure 2a shows a slow loss of approximately 5% per day of CD34-positive cells under all storage conditions. CFU-GM and BFU-E Bone Marrow Transplantation were rapidly lost during the first 3 days in CPDA-1 WB, whereas a more constant decrease over 7 days was noted for the other conditions (Figure 2b, c) . CFU-GM preservation was best in Ca-free L15 at 22°C, but for BFU-E superiority of the Ca-free L15 medium could not be demonstrated (Figure 2b, c) .
To gain more insight into the fate of the progenitor cells during the 7-day storage period in Ca-free L15 at either 22°C or 4°C, LTC-IC were enumerated together with the committed progenitors in freshly drawn WB and after 7 days of storage in three consecutive experiments. Figure 3 shows that 90 ϩ 14% of LTC-IC remain after 7 days in Ca-free L15 at 22°C. Still, 58 Ϯ 9% of LTC-IC were preserved at 4°C in Ca-free L15. The average number of colonies formed (output) per LTC-IC was 9.9 Ϯ 4.0% at day 0. After 7 days, an output of 10.8 Ϯ 6.9% and 4.4 Ϯ 3.8% was found for Ca-free L15 at 22°C and at 4°C, respectively. A similar experiment with citrate WB at 22°C showed that under this condition, 57 Ϯ 32% (n ϭ 3) of LTC-IC could be maintained. Table 6 Phenotypic progenitor profile after storage of mobilized whole blood for 7 days
Day 0
Ca-free L15 Ca-free L15 22°C 4°C 
Marker expression on progenitors in mobilized whole blood after 7 days
Co-expression on CD34-positive cells of stem cell phenotypes and L-selectin, VLA-4/5 and CXCR4 expression was also measured in the WB samples of Figure 3 . No differences were found in the expression of Thy-1, c-kit and AC133 on CD34-positive cells after 7 days (Table 6) . Although the proportion of CD34 ϩ CD38 dim/Ϫ cells was very low, storage at 4°C seemed to halve the number of CD34 ϩ CD38 dim/Ϫ cells, in accordance with the decrease in LTC-IC (Figure 3) .
The expression of the integrins VLA-4 and VLA-5 remained unchanged. Although the average percentage of L-selectin-positive cells did not change, a decrease in the fluorescence intensity was noted which was more pronounced at 22°C. The variation of CXCR4 expression on fresh WB CD34-positive cells was very high (positivity between 2.7 and 85%) and therefore the individual data are given in Table 6 . In those cases with an initial high CXCR4 expression, it was also noted that the fluorescence intensity decreased at 22°C but remained unchanged at 4°C.
Scaling up of sample size
So far, all experiments have been performed in tissue culture flasks. This set-up implicates a large air-fluid interface, allowing exchange of O 2 and CO 2 . Without exchange, the pCO 2 will increase to levels that cause a severe decrease in pH. Also, severe anoxia is very likely harmful to at least the committed progenitors. 29 Since storage in tissue culture flasks is not feasible for larger volumes, gas-permeable tissue culture bags containing 100 ml of citrate WB and 43 ml of Ca-free L15 medium (30% medium volume) were tested for their ability to exchange gases, and results were . In culture bags, 105 Ϯ 49 mmHg (pO 2 , not significant) and 11 Ϯ 2 mmHg (pCO 2 , P Ͻ 0.01) were found, respectively (n ϭ 9). In these experiments, BFU-E recovery after 7 days was 42 Ϯ 11% in flasks and 36 Ϯ 11% in bags. CFU-GM recoveries of 45 Ϯ 20% (flasks) and 49 Ϯ 26% (bags) were found. These results indicate that it is practicable to store larger volumes of WB in gas-permeable bags in a clinical setting.
Discussion
In this study, we have demonstrated that by using a modified Leibovitz's L15 medium, approximately 90% of the LTC-IC and CD34-positive cells of G-CSF mobilized whole blood can be preserved during unfrozen storage for at least 7 days. Committed progenitor recovery was 40-50%. These results are comparable with recovery data reported after cryopreservation of PBSC (70-90% for nucleated cells, 33-80% for committed progenitors. 12, [30] [31] [32] [33] [34] [35] In the experiments described in Table 4 , three washes were performed before the addition of medium. As a consequence, recovery data were variable. Besides, this approach is not very practical for application in transplantation. Therefore, a calcium-free L15 was obtained, which could be directly added to citrated WB without any manipulation. Using this calcium-free medium, similar results were obtained, but with lower variability. More importantly, more than 20% recovery of committed progenitors was always found, whereas after cryopreservation of PBSC individual samples with only 0-1% recovery have been reported. 32, 33 A storage period of 7 days is sufficient to cover most high-dose schemes, and would allow a wider range of Bone Marrow Transplantation applications for unprocessed G-CSF mobilized WB, provided that enough stem cells can be collected in 1 liter. Generally, 2.0 ϫ 10 6 /kg CD34-positive cells are required for safe hematological recovery. However, this threshold is based on the number of viable CD34-positive cells in the graft before cryopreservation. We have recently found that after cryopreservation, 66% (range 14-96%) of the CD34-positive cells present in PBSC transplants are early apoptotic (example shown in Figure 1a) . 27 On the other hand, after 7 days more than 90% of the CD34-positive population in WB was viable. Thus, the effective cell dose of a cryopreserved stem cell graft of 2.0 ϫ 10 6 CD34-positive cells/kg would only be 0.8 ϫ 10 6 /kg. These results suggest that an unfrozen stem cell transplant might not need a minimum of 2.0 ϫ 10 6 CD34-positive cells per kg. Indeed, we have found that transplantation of 3-days' stored WB grafts containing a CD34 cell dose of Ͼ0.3 ϫ 10 6 per kg resulted in rapid hematological recovery after a BEAM-like regimen. 9 This threshold was reached in 90% of patients. In the present study, some patients would not have reached this threshold, and most patients would not have reached 2.0 ϫ 10 6 CD34/kg. This was due to the fact that test samples were taken from a heterogeneous group consisting of many heavily pretreated patients, who sometimes needed as many as 5-10 leukaphereses to harvest 2.0 ϫ 10 6 /kg CD34-positive cells.
Previous studies using CPD or ACD-A generally showed very poor recovery (Ͻ10%) of clonogenic cells after 7 days at either 4°C or 20°C. 12, 15, 16, 18 Using heparin, Lasky et al 17 showed better recoveries after storage at 22°C. 17 From the experiments in Table 3 , it was learned that replacement of CPDA-1 by citrate led to both a stable pH and improvement of CFU-GM preservation at room temperature. At 22°C, glucose, which is abundantly present in CPDA-1 (2.9 g/dl), is metabolized rapidly into lactate and CO 2 , resulting in a drop in pH. Deviation of culture pH has been shown to affect both the cloning efficiency and differentiation potential of progenitor cells, 36, 37 and indeed in separate experiments with mononuclear cells, a pH of 6.8 or lower negatively influenced CFU-GM recovery. Therefore, we hypothesized that either a strong buffer or an alternative to glucose, resulting in less lactate production, should be used. Several cell culture media were tested for this purpose (Table 4 ), but most of them did not substantially improve CFU-GM preservation. Moreover, despite the presence of HCO 3 Ϫ and/or Hepes buffer systems the pH was not always optimally controlled. In fact, results were not better than previously reported attempts at liquid storage of hematopoietic progenitors. 12, [15] [16] [17] [18] However, the use of Leibovitz's L15 significantly improved CFU-GM recovery. At the same time, pH remained much more constant during the 7 days. Leibovitz's L15 medium contains galactose instead of glucose, and high concentrations of free-base forms of amino acids, both contributing to a tight control of pH. Glucose metabolism is dependent on the rate of glycolysis in normal cells, which occurs rather rapidly under normal circumstances. 38 Galactose is also metabolized along this pathway but at a slower rate, and thus results in lower lactate production. 38, 39 These observations led to the development of a culture medium not requiring a complex buffer system. [40] [41] [42] So far, no experience has been obtained with (human) hematopoietic cells. Table 4 shows that indeed a better control of pH was found using L15 medium, although the range was still very wide. However, in a study of Burger et al 43 very tight control of pH during storage of PBPC by using STM-sav did not significantly improve CFU recovery in comparison with normal glucose-containing cell culture media. The better preservation of clonogenic cells in L15 medium could therefore be also due to the more effective metabolism of the 'slow-release' carbohydrate in this medium.
Most data in this study were obtained from clonogenic assays. Despite the high LTC-IC and CD34-positive cell viability after 7 days, committed progenitor cell recovery was lower. To see whether changes in outcome of clonogenic assays could be related to phenotypic changes of CD34-positive cells, the expression of some primitive markers and adhesion molecules was measured. neg phenotype are enriched for more primitive progenitor cells. [44] [45] [46] [47] [48] [49] [50] Adhesion molecules like L-selectin, VLA-4 and VLA-5, and the chemokine receptor CXCR4 are likely associated with engraftment. [51] [52] [53] No significant changes occurred in the expression of early markers after 7 days under all conditions. Also, no clear changes in Lselectin, VLA-4, VLA-5 and CXCR4 expression were found. Thus, differentiation of CD34-positive cells throughout the storage period does not seem to be the explanation for the reduction of CFU-GM, and it might thus be that committed progenitors are more vulnerable to environmental changes than LTC-IC, leading to a reduced outgrowth, but not phenotypical and/or apoptotic changes.
In conclusion, we have demonstrated that the standard anticoagulant CPDA-1 is far from optimal for preservation of hematopoietic progenitors, and that by using a modified Leibovitz's L15 medium adequate numbers of clonogenic cells can be maintained in G-CSF mobilized whole blood for 7 days. The recovery of stem cells as measured by the CFU-GM assay was approximately 50%, whereas up to 90% of the more primitive stem cells (LTC-IC) were preserved. These data would allow the use of autologous WB transplantation after most high-dose chemotherapy regimens. The current results encourage further exploration of the safety of a 7-days' stored WB transplant for clinical use.
